Bayer's High-Stakes Gamble: A Supreme Court Showdown and a Blockbuster Drug

The German pharmaceutical and agricultural giant Bayer is entering a period of intense pressure, where a potential legal breakthrough in the United States collides with the financial drag of past liabilities. The company is simultaneously banking on the soaring sales of its prostate cancer drug Nubeqa to fuel a future turnaround, while navigating a precarious cash position.

The Legal Crossroads: A Supreme Court Verdict Looms

The most pivotal date on Bayer’s calendar is April 27, 2026, when the U.S. Supreme Court will hear oral arguments in a case concerning its Roundup herbicide. The company’s core legal argument is that federal law, as administered by the Environmental Protection Agency (EPA), should preempt state-level claims that the product lacked a cancer warning. The U.S. Department of Justice has sided with Bayer on this point, though a coalition of state attorneys general is pushing back.

A favorable ruling from the high court, expected by the end of June, would effectively dismantle the legal foundation for thousands of future Roundup lawsuits. To hedge its bets, Bayer is also advancing a separate settlement package in Missouri worth over $7 billion, which has received preliminary approval. Claimants have until June 4 to opt out of this deal, creating a dual safety net for the company.

The Financial Toll: A Deep Hole Before the Climb

The legal saga is exacting a heavy price on Bayer’s balance sheet. The company has set aside nearly €12 billion in provisions for litigation. This year alone, cash outflows related to the U.S. glyphosate cases are expected to consume roughly €5 billion. This burden is the primary driver behind a projected negative free cash flow of up to €2.5 billion for 2026.

Should investors sell immediately? Or is it worth buying Bayer?

As a result, net financial debt is forecast to swell to as much as €33 billion by year-end. Despite these headwinds, management has reaffirmed its full-year guidance. The company is targeting currency-adjusted sales of between €45 billion and €47 billion, with EBITDA before special items coming in at around €10 billion.

A Drug on the Rise: Nubeqa’s Meteoric Ascent

Amid the legal and financial turmoil, Bayer’s pharmaceutical division is providing a bright spot. The prostate cancer treatment Nubeqa has seen its sales surge by 57% to €2.4 billion, making it a cornerstone of the company’s growth strategy. Pharma chief Stefan Oelrich is betting on this momentum, along with the heart drug Kerendia—which is targeting peak sales of over €3 billion—to drive a return to growth by 2027.

However, the company’s most important market, the U.S., is also a source of new risks. The threat of tariffs as high as 100% on patented medicines is forcing Bayer to explore expanding local production. Simultaneously, a U.S. government order requiring drugmakers to align American prices with international levels is adding pricing pressure. To offset these potential discounts, Bayer is demanding higher premiums from governments in Europe and Japan.

Bayer at a turning point? This analysis reveals what investors need to know now.

The Shareholder Calendar: A Week of Reckoning

Investors are bracing for a dense schedule of events. The annual general meeting on April 24 will see a vote on a dividend of €0.11 per share. This coincides with the ex-dividend date, which falls on the same day as the Supreme Court hearing. The first-quarter results are due on May 12, which will provide the first concrete look at whether the operational business can meet expectations.

The stock closed at €39.97 on Tuesday, having gained roughly 5% since the start of the year. While the share price is up about 12% year-to-date, the relative strength index (RSI) of 23.3 suggests the stock is currently in oversold territory, indicating that much of the bad news may already be priced in. The coming weeks will determine whether Bayer’s legal strategy can deliver a knockout blow to its biggest liability, or if the company must continue to fight a costly, drawn-out battle.

Ad

Bayer Stock: New Analysis - 22 April

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

en | DE000BAY0017 | BAYERS | boerse | 69235027 |